Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma

NCT03815058 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03815058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03815058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 21, 2018
Completion date
January 21, 2025
Enrollment
131 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma